Drugs / EB01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03680131 | Oct 2019 → Sep 2022 | allergic contact dermatitis | Edesa Biotech Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EB01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03680131 ↗ |
| Route | Topical | “Topically Applied EB01 Cream” NCT03680131 ↗ |